Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18818974 | METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONS | August 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18733576 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2024 | September 2024 | Allow | 3 | 1 | 0 | No | No |
| 18634717 | METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18598719 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18444443 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18402138 | BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE | January 2024 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18511852 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18495932 | METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONS | October 2023 | March 2024 | Allow | 5 | 2 | 0 | No | No |
| 18491099 | Reagents and methods for treating bacterial infection | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18461912 | Treatment of Rhinosinusitis with P-glycoprotein Inhibitors | September 2023 | November 2024 | Allow | 15 | 2 | 0 | No | No |
| 18454855 | ANTIMICROBIAL PEPTIDE SPAMPCIN56-86 FROM SCYLLA PARAMAMOSAIN AND APPLICATIONS THEREOF | August 2023 | June 2024 | Allow | 9 | 1 | 0 | No | No |
| 18450056 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18355223 | Controlled-Release PTH Compound | July 2023 | October 2023 | Allow | 3 | 1 | 0 | No | No |
| 18354076 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS | July 2023 | December 2024 | Allow | 17 | 3 | 0 | No | No |
| 18222170 | PROCESS FOR THE PREPARATION OF CYCLIC DEPSIPEPTIDES | July 2023 | November 2024 | Allow | 16 | 1 | 0 | No | No |
| 18340707 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2023 | November 2023 | Allow | 4 | 2 | 0 | Yes | No |
| 18327086 | SALTY TASTE ENHANCING PEPTIDE DERIVED FROM DRY-CURED HAM AND PREPARATION METHOD THEREOF | June 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18202103 | STABLE LIQUID COMPOSITIONS OF GLUCAGON | May 2023 | September 2024 | Allow | 16 | 3 | 0 | Yes | No |
| 18320544 | PROCESS OF MAKING ABALOPARATIDE | May 2023 | August 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18308892 | NOVEL IL10 AGONISTS AND METHODS OF USE THEREOF | April 2023 | August 2024 | Allow | 16 | 1 | 0 | No | No |
| 18139825 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | April 2023 | December 2024 | Allow | 19 | 1 | 0 | No | No |
| 18193144 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18189997 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | March 2023 | October 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18176372 | Dosage Regimen for a Controlled-Release PTH Compound | February 2023 | November 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18158712 | USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION | January 2023 | August 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18158002 | Methods and Compositions for Delivery of Biotin to Mitochondria | January 2023 | August 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18157752 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18157756 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18157739 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2023 | September 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18157766 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | January 2023 | July 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18154522 | SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROIN | January 2023 | November 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18151155 | GLYCOPEPTIDE COMPOSITIONS | January 2023 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18082133 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | December 2022 | July 2024 | Allow | 19 | 2 | 1 | No | No |
| 18066396 | Methods and Compositions for Delivery of Biotin to Mitochondria | December 2022 | May 2024 | Allow | 17 | 5 | 0 | Yes | No |
| 18080057 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATORY CONDITIONS | December 2022 | September 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18063294 | Controlled-Release PTH Compound | December 2022 | June 2023 | Allow | 6 | 2 | 0 | No | No |
| 18075971 | AMINO ACID COMPOSITIONS AND METHODS OF MANUFACTURING THE COMPOSITIONS | December 2022 | September 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18061084 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | December 2022 | August 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18059718 | ANTI-INFECTIVE FORMULATIONS | November 2022 | July 2024 | Allow | 20 | 2 | 0 | No | No |
| 17954001 | MODIFIED COLLAGEN, METHODS OF MANUFACTURE THEREOF | September 2022 | November 2024 | Allow | 26 | 1 | 1 | No | No |
| 17946447 | FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17946394 | Methods and Compositions for Delivery of Biotin to Mitochondria | September 2022 | February 2023 | Allow | 5 | 2 | 0 | Yes | No |
| 17932180 | SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF | September 2022 | April 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17943532 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE | September 2022 | February 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 17900450 | MATERIALS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | August 2022 | August 2024 | Allow | 24 | 2 | 0 | No | No |
| 17820337 | ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS | August 2022 | April 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17883492 | COMPOSITIONS, METHODS, AND SYSTEMS FOR ORALLY ADMINISTRABLE AFFINITY-BASED PROTEIN | August 2022 | March 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17881286 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH | August 2022 | June 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17874831 | WOUND TREATMENT CONTAINING COLLAGEN AND A GELATIN-REDUCING AGENT, AND METHOD FOR PROMOTING WOUND HEALING | July 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17860642 | Glycopeptide Compositions | July 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17858629 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | July 2022 | June 2023 | Allow | 12 | 3 | 0 | No | No |
| 17856729 | CELL-PROTECTING COMPOSITION CONTAINING CYCLO HISTIDINE-PROLINE AS ACTIVE INGREDIENT | July 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17850976 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES | June 2022 | July 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17848180 | CNP PRODRUGS | June 2022 | September 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17847086 | PEPTIDOMIMETIC MACROCYCLES | June 2022 | April 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17844816 | Methods and Compositions for Delivery of Biotin to Mitochondria | June 2022 | January 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 17832612 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | June 2022 | February 2024 | Abandon | 21 | 1 | 0 | Yes | No |
| 17756376 | IMMODULATOR PEPTIDES COVALENTLY MODIFIED WITH SMALL MOLECULES | May 2022 | June 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17751451 | RAS INHIBITORY PEPTIDES AND USES THEREOF | May 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17707857 | KLK5 INHIBITORY PEPTIDE | March 2022 | February 2024 | Allow | 23 | 1 | 1 | No | No |
| 17705607 | METHOD FOR PREPARING PEPTIDES | March 2022 | January 2024 | Allow | 22 | 1 | 0 | No | No |
| 17673703 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | February 2022 | November 2024 | Abandon | 33 | 1 | 1 | Yes | No |
| 17650570 | SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROIN | February 2022 | November 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17667330 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | February 2022 | June 2022 | Allow | 5 | 2 | 0 | Yes | No |
| 17665947 | USE OF SELF-ASSEMBLING POLYPEPTIDES AS TISSUE ADHESIVES | February 2022 | August 2024 | Allow | 30 | 3 | 1 | Yes | No |
| 17562861 | HER3 Peptides for Imaging and Radiotherapy | December 2021 | January 2025 | Allow | 36 | 3 | 1 | Yes | No |
| 17545217 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | December 2021 | May 2024 | Allow | 29 | 2 | 1 | No | No |
| 17545995 | CHLORIDE SALT OF TAT-NR2B9C | December 2021 | October 2023 | Allow | 22 | 2 | 0 | No | No |
| 17541019 | METHODS OF TREATMENT FOR BACTERIAL INFECTIONS | December 2021 | March 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17540549 | VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS | December 2021 | December 2023 | Allow | 24 | 2 | 0 | No | No |
| 17539727 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | December 2021 | July 2023 | Allow | 19 | 1 | 0 | No | No |
| 17526481 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | November 2021 | March 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17518247 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | November 2021 | July 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17514469 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | October 2021 | November 2024 | Abandon | 36 | 2 | 0 | No | Yes |
| 17606864 | LIPID-CONTROLLED RELEASE COMPOSITIONS | October 2021 | December 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17606699 | A YEAST-FERMENTED RECOMBINANT FIBRONECTIN PEPTIDE IN SMALL MOLECULE, AND ITS PREPARATION METHOD AND APPLICATIONS THEREOF | October 2021 | December 2024 | Allow | 38 | 2 | 0 | No | No |
| 17500735 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | October 2021 | June 2022 | Allow | 9 | 2 | 1 | Yes | No |
| 17499859 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | October 2021 | May 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17493551 | METHODS FOR REDUCING OXIDATIVE DAMAGE | October 2021 | January 2025 | Abandon | 39 | 2 | 0 | No | Yes |
| 17489495 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | September 2021 | January 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17479101 | POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
| 17478027 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | September 2021 | February 2022 | Allow | 5 | 1 | 0 | No | No |
| 17474114 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS | September 2021 | April 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17439163 | IRISIN IMPROVES PLACENTAL FUNCTION DURING PREGNANCY | September 2021 | December 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17472574 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROME | September 2021 | September 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17470696 | AGENTS THAT INHIBIT NGLY1 AND METHODS OF USE THEREOF | September 2021 | September 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17469102 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | September 2021 | January 2024 | Allow | 28 | 2 | 0 | No | No |
| 17466661 | Methods and Compositions for Delivery of Biotin to Mitochondria | September 2021 | May 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17397796 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | August 2021 | September 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17395369 | VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS | August 2021 | September 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17389571 | METHODS FOR TREATMENT OF COVID-19 SYNDROME | July 2021 | May 2023 | Allow | 21 | 0 | 0 | Yes | No |
| 17443445 | METHODS FOR DISRUPTING BIOFILMS | July 2021 | December 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17310186 | SYNTHESIS STRATEGY FOR GAP PROTECTING GROUP | July 2021 | July 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17373369 | SYNTHESIS METHOD OF CYCLOSPORINE DERIVATIVES | July 2021 | August 2023 | Allow | 25 | 1 | 0 | No | No |
| 17371475 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | July 2021 | August 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17366463 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | July 2021 | July 2024 | Abandon | 36 | 2 | 0 | Yes | No |
| 17364804 | Skin Protectant Paste | June 2021 | April 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17361087 | CIRCULAR TANDEM REPEAT PROTEINS | June 2021 | September 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17351723 | Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists | June 2021 | January 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17350723 | Heat Shock Protein-Binding Peptide Compositions And Methods Of Use Thereof | June 2021 | October 2023 | Abandon | 28 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RUSSEL, JEFFREY E.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RUSSEL, JEFFREY E works in Art Unit 1654 and has examined 1,334 patent applications in our dataset. With an allowance rate of 69.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner RUSSEL, JEFFREY E's allowance rate of 69.8% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by RUSSEL, JEFFREY E receive 1.72 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by RUSSEL, JEFFREY E is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +36.8% benefit to allowance rate for applications examined by RUSSEL, JEFFREY E. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.8% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 68.3% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 96.4% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 96.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 74.7% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.3% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.